mTOR

Target
  1. p110α (1)
  2. p110γ (1)
Actions
  1. Inhibitor (34)


Items 1 to 25 of 34 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Application Product Information
A11303

AZD2014

mTORC1/2 inhibitor
AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor.
A10114

AZD8055

mTOR Inhibitor
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM.
A10133

BEZ235 (NVP-BEZ235, Dactolisib)

PI3K/mTOR Inhibitor
BEZ235 (NVP-BEZ235) inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes.
A13078

CC-223

mTOR Inhibitor
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3K-alpha (IC50=4uM).
A10295

Deforolimus (Ridaforolimus)

mTOR Inhibitor

Deforolimus (Ridaforolimus) is an investigational targeted and small-molecule inhibitor of the protein mTOR. Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.

A10374

Everolimus (RAD001)

mTOR inhibitor
Everolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an mTOR inhibitor.
A11443

GDC-0349

mTOR inhibitor
GDC-0349 is under evaluating the Safety and Tolerability in Patients with locally advanced or metastatic solid tumors or non hodgkin's lymphoma.
A11023

GDC-0980 (Apitolisib, RG7422)

mTOR/PI3K Inhibitor
GDC-0980 (RG7422) is a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 α, β, δ and γ isoforms, respectively.
A13992

GNE-317

PI3K/mTOR inhibitor
GNE-317 is a potent PI3K/mTOR inhibitor that can cross the blood?Cbrain barrier; shows potent suppression of the PI3K pathway in the brain of mice with intact BBB.
A11035

GSK2126458

mTOR/PI3K Inhibitor,
GSK2126458 is a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.
A11461

INK 128 (MLN0128)

mTOR inhibitor
INK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
A10505

KU-0063794

mTOR Inhibitor
KU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively).
A16126

LY3023414

PI3K/mTOR Dual Inhibitor
LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK, extracted from patent WO/2012097039A1, compound example 1, has an IC50 of 64.9 nM, 42.1 nM, 10.6 nM, 19.1 nM for Akt1(pT308), Akt1 (pS473), P70S6(pT389), S6RP(pS240/242).
A15508

MHY1485

mTOR inhibitor
MHY1485 is a mTOR activator; inhibits the autophagic process by inhibition of fusion between autophagosomes and lysosomes leading to the accumulation of LC3II protein and enlarged autophagosomes.
A15175

mTOR inhibitor (mTOR-IN-1)

mTOR inhibitor
mTOR inhibitor is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 1.5 nM.
A11056

OSI-027

mTOR inhibitor
OSI-027 is a potent, selective and orally bioavailable mTOR kinase inhibitor that inhibits the kinase activity associated with both the TORC1 and TORC2 complexes of mTOR.
A11024

PF-04691502

PI3K/mTOR Inhibitor
PF-04691502 is a PI3K/mTOR kinase inhibitor, is also an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway.
A12935

PF-04979064

PI3K/mTOR Dual Inhibitor
PF-04979064 is a highly potent and orally bioavailable PI3K/mTOR dual inhibitor.
A11079

PKI-587 ( Gedatolisib )

PI3K/mTOR inhibitor
PKI-587 is a highly potent PI3K/mTOR kinase inhibitor that inhibits PI3K-α,β,γ, δ isoforms and mTOR with IC50 of 0.4, 6.0, 5.4, 6.0 and 1.6 nM respectively.
A10746

PP242

mTOR Inhibitor
PP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2.
A11537

QL-IX-55

mTORC1/2 inhibitor
QL-IX-55 is a selective ATP-competitive inhibitor of mTORC1/2 with IC50s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively.
A10782

Rapamycin (Sirolimus)

mTOR Inhibitors
Rapamycin (Sirolimus) prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).
A16276

SAR245409

PI3K/mTOR dual inhibitor
SAR245409 is a PI3K/mTOR dual kinase inhibitor XL765 is an orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity.
A12704

SF1126

Pan PI3K inhibitor
SF1126 is a water soluble, small-molecule prodrug containing the pan-PI3K/mTOR inhibitor LY294002/SF1101 conjugated to the RGD-containing tetra-peptide SF1174 with potential antineoplastic and antiangiogenic activities.
A10906

Temsirolimus (Torisel)

mTOR inhibitor
Temsirolimus is a specific inhibitor of mTOR and interferes with the synthesis of proteins that regulate proliferation, growth, and survival of tumor cells.

Items 1 to 25 of 34 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction